Hempalta Past Earnings Performance
Past criteria checks 0/6
Hempalta's earnings have been declining at an average annual rate of -43.2%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 32.4% per year.
Key information
-43.2%
Earnings growth rate
18.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 32.4% |
| Return on equity | -43.8% |
| Net Margin | -484.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hempalta makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -3 | 2 | 0 |
| 31 Mar 24 | 0 | -2 | 1 | 0 |
| 31 Dec 23 | 0 | -2 | 1 | 0 |
| 30 Sep 23 | 0 | -2 | 1 | 0 |
| 30 Sep 22 | 0 | -2 | 1 | 0 |
Quality Earnings: HEMP is currently unprofitable.
Growing Profit Margin: HEMP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if HEMP's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare HEMP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HEMP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-44%).
Return on Equity
High ROE: HEMP has a negative Return on Equity (-43.84%), as it is currently unprofitable.